Spikevax Moderna COVID
Selected indexed studies
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. (N Engl J Med, 2021) [PMID:33378609]
- COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. (Eur Rev Med Pharmacol Sci, 2021) [PMID:33629336]
- Role of COVID-19 Vaccines in SARS-CoV-2 Variants. (Front Immunol, 2022) [PMID:35669787]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. (2021) pubmed
- Role of COVID-19 Vaccines in SARS-CoV-2 Variants. (2022) pubmed
- Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273. (2022) pubmed
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. (2021) pubmed
- Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia. (2023) pubmed
- COVID-19 updates: Moderna COVID-19 vaccine (Spikevax) gains full licensure. (2022) pubmed
- COVID-19 vaccine induced myocarditis in young males: A systematic review. (2023) pubmed
- Surveillance for Adverse Events After COVID-19 mRNA Vaccination. (2021) pubmed
- COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series. (2023) pubmed
- SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. (2020) pubmed